A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective Response Rate
WHO criteria
baseline to measured progressive disease, every three weeks
No
Shukui Qin, MD
Principal Investigator
The 81st Hospital of Chinese PLA
China: Food and Drug Administration
SIM-90
NCT01327235
March 2011
February 2014
Name | Location |
---|